← All trials
NCT04327011
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2011
- Primary completion
- Dec 31, 2019
- Completion date
- Dec 31, 2019
- First posted
- Mar 30, 2020
- Last posted
- Mar 30, 2020
- Enrollment
- 65
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tocagen Inc.Lead sponsor
- The Cleveland ClinicOverall official - principal investigator
- Tocagen Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.